Comorbid addictive disorders and schizophrenia in the aspect of pathogenesis and treatment

Eryshev O.F.; Arkad'ev V.V.

doi:https://doi.org/

Close metadata

Recommended articles:

Analysis of cognitive status in patients with different nosologies and clinical variants of very late manifesting schizophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93

Efficacy of dupilumab application in bullous pemphigoid proceeding in presence of bronchial asthma. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):204-209

Review and resolution of the Council of Experts on the topic «The role of the combination of undenatured type II collagen UC-II, vitamin C, and trace elements in recovering and maintaining the function of the musculoskeletal system, and preservation of health of the joints». Russian Journal of Preventive Medicine. 2025;(4):102-110

Prognostic factors for progression and risk chronic obstructive pulmonary disease adverse outcomes. Journal of Respiratory Medicine. 2025;(2):71-78

Modern concepts of sleep disturbances associated with mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12

Association of cortisol levels with psychopathological features of depression and therapeutic response in female patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):45-54

Factors supporting chronic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15

Features of depressive disorders and suicidal behavior in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):7-13

Attention deficit hyperactivity disorder in adolescents. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):42-49

Attention deficit hyperactivity disorder: pharmacotherapy in special situations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):59-65

Abstract:

Combinations of schizophrenia with addictive disorders are common in clinical practice. Some hypotheses were posited to explain this phenomenon with the biochemical hypothesis being the most common. A vast body of evidence supports the similarity in the pathogenesis of addiction and schizophrenia. Biochemical data on the pathogenesis of both diseases are used for treatment recommendations. However there are many discrepancies in this field and future research is needed.

Keywords:

addictive disorders

schizophrenia

comorbidity

biochemical mechanisms

neuroleptics

Authors:

Eryshev O.F.

Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva

Arkad'ev V.V.

Kemberlendskiĭ tsentr psikhicheskogo zdorov'ia, Kentukki, SShA

Close metadata

References:

Anokhina I.P. Osnovnye biologicheskie mekhanizmy alkogol'noi i narkoticheskoi zavisimosti. Rukovodstvo po narkologii. Pod red. N.N. Ivantsa. M: Medpraktika-M 2002;1:33-41.
Pyatnitskaya I.N. Klinicheskaya narkologiya. L: Meditsina 1975.
Addington J., Addington D. Effect of substance misuse in early psychosis. Br J Psychiat 1998;172:134-136.
Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am J Psychiat 1978;135:1081-1084.
Anton R.F., Kranzler H., Breder C. et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 2008;28:5-12.
Balla et al. Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum. Neurochem Res 2001;26:1001-1006.
Bell D.S. Comparison of amphetamine psychosis and schizophrenia. Br J Psychiat 1965;111:701-701.
Brown E.S., Jeffress J., Liggin J.D. et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiat 2005;66:756-760.
Brunett M.F., Noordsy D.L., Green A.I. Pharmacological treatment for co-occurring substance use disorders in patients with schizophrenia: a research review. J Dual Diagn 2005;1:41-55.
Brunette M.F., Drake R.E., Xie H. et al. Clozapine use and relapse of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bull 2006;32:637-643.
Buckley P.F. Substance abuse in schizophrenia: a review. J Clin Psychiat 1998;59:Suppl 3:26-30.
Buckley P.F., McCarthy M., Chapman P. et al. Clozapine treatment of comorbid substance abuse in patients with schizophrenia. Schizophrenia Res 1999;36:272.
Carlsson A. Does dopamine play a role in schizophrenia? Psychol Med 1977;7:583-597.
Carlsson A. Mechanism of action of neuroleptic drugs. In: Psychopharmacology: a generation in progress. Eds. M.A. Lipton, A. Di Mascio, K.F. Killian. New York: Raven Press 1978;1057-1070.
Carol G., Smelson D.A., Losonczy M.F., Ziedonis D. Alcohol and drug abuse: a preliminary investigation of cocaine craving among persons with and without schizophrenia. Psychiat Service 2001;52:1029-1031.
Caspi A., Moffitt T.E., Cannon M. et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene environment interaction. Biol Psychiat 2005;57:1117-1127.
Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiat 2001;50:71-83.
Croissant B., Klein O., Gehrlein L. et al. Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur Psychiat 2006;21:570-573.
Cuesta M.J., Peralta V., Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophrenia Res 2001;48:17-28.
Di Chiara et al. Drug addiction as a disorder of associative learning: role of nucleus accumbens shell/extended amygdale dopamine. Annals of the New York Academy. Science 1999;877:461-485.
Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Res 1999;35:Suppl:93-100.
Drake R.E., Xie H., McHugo G.J., Green A.I. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bull 2000;26:441-449.
Finch L.H. Neurophysiology of converging synaptic inputs from the rat prefrontal cortex, amygdala, midline thalamus, and hippocampal formation onto single neurons of caudate/putamen and nucleus accumbens. Hippocampus 1996;6:495-512.
Funahashi S., Kubota K. Working memory and prefrontal cortex. Neurosci Res 1994;21:1-11.
George T.P., Vessiccho J.C., Termine A. et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002;26:75-85.
Gonzalez P. et al. Decreased of tolerance to, and physical dependence on, morphine by glutamate receptors antagonists. Eur J Pharmacol 1997;332:257-262.
Grace A.A. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend 1995;37:111-129.
Green A.I., Zimmet S.V., Strous R.D., Schildraut J.J. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Rev Psychiat 1999;6:287-296.
Green A.I., Burgess E.S., Dawson R. et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia Res 2003;60:81-85.
Green A.I., Tohen M.F., Hamer R.M. et al. HGDH Research Group: First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Res 2004;66:125-135.
Green A.L., Noordsy D.L., Brunette M.F., O’Keefe C.D. Substance abuse and schizophrenia: Pharmacotherapeutic intervention. J Substance Abuse Treat 2008;34:61-71.
Hambrecht M., Hafner H. Substance abuse and onset of schizophrenia. Biol Psychiat 1996;40:1155-1163.
Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiat 2001;158:176-184.
Iber F.L., Lee K., Lacoursiere R., Fuller R. Liver toxicity encountered in the Veterans Administration trail of disulfiram in alcoholics. Alcohol Clin Exper Res 1987;11:301-304.
Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999;20:201-228.
Kalivas P.W., Duffy P., Barrow J. Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J Pharmacol Exp Ther 1989;251:378-387.
Kalivas P.W., Duffy P. Repeated cocaine administration alters extracellular glutamate in the ventral tegmental area. J Neurochem 1998;70:1497-1502.
Khantzian E.J. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harvard Rev Psychiat 1997;4:231-244.
Kingsbury S.J., Salzman C. Disulfiram in the treatment of alcoholic patients with schizophrenia. Hospital Commun Psychiat 1990;41:133-134.
Knable M.B., Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 1997;11:1123-1131.
Kofoed L., Kania J., Walsh T., Atkinson R.M. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiat 1986;143:867-872.
Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sciences 1992;13:177-184.
Krupitsky E.M., Neznanova O., Masalov D. et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiat 2007;164:3:519-523.
Krystal J.H., Petrakis I.L., Mason G., D’Souza D.C. NMDA glutamate receptors and alcoholism: rewards, dependence, treatment, and vulnerability. Pharmacol Therap 2003;99:79-94.
Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995;13:9-19.
Lieberman J.A., Stroup T.S., McEvay J.P. et al. and the CATIE Investigators: Effectiveness of antipsychotic drug in patients with chronic schizophrenia. New Engl J Med 2005;353:1209-1223.
Liljequist S. NMDA receptor antagonists inhibit ethanol-produced locomotor stimulation in NMRI mice. Alcohol 1991;8:309-312.
Lodge D., Johnson K.M. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci 1990;11:81-86.
Mansvelder H.D., McGehee D.S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 2000;27:349-357.
Markou A., Kosten T.R., Koobs G.F. Animal models of drugs craving. Psychopharmacology 1993;112:163-182.
Mogenson G.J., Jones D.L., Yim C.Y. From motivation to action: functional interface between the limbic system and the motor system. Progr Neurobiol 1980;14:69-97.
Mueser K.T., Noordsy D.L., Fox L., Wolfe R. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 2003;12:242-252.
Mueser K.T., Noordsy D.L., Drake R.E., Fox L. Integrated Treatment for Dual Disorders: A Guide To Effective Practice. New York: Guilford Publications 2003;3-49.
Newcomer J.W., Farber N.B., Jevtovic-Todorovic V. et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999;20:106-118.
Noordsy D.L., O’Keefe C.D., Mueser K.T., Xie H. Switching to olanzapine in naturalistic community care. Presented at:154th Annual Meeting of the American Psychiatric Association. New York 2001.
Noordsy D.L., O’Keefe C.D., Mueser K.T. Four-year outcomes of naturalistic olanzapine or conventional antipsychotics. Presented at: 57th Institute on Psychiatric Service. San Diego CA 2005.
Petrakis I.L., O’Malley S., Rounsaville B. et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004;172:291-297.
Petrakis I.L., Leslie D., Finney J.W., Rosenheck R. Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. Am J Addict 2006;15:44-49.
Petrakis I.L., Nich C., Ralevski E. Psychotic spectrum disorders and alcohol abuse: A review of pharmacotheraputic strategies and report on the effectiveness of naltrexone and disulfiram. Schizophrenia Bull 2006;32:644-654.
Potkin S., Pampoulova T., Mancini-Marië A. et al. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiat 2006;77:796-798.
Potvin S., Stip E., Lipp O. et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 2006;22:1277-1285.
Regier D.A., Farmer M.E., Rae D.S. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) study. J Am Med Ass 1990;264:2511-2518.
Rubio G., Martínez I., Ponce G. et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canad J Psychiat 2006;51:531-539.
Shoaib M., Stolerman I.P. MK801 attenuates behavioral adaptation to chronic nicotine administration in rats. Br J Pharmacol 1992;105:514-515.
Smelson D.A., Tunis S.L., Nyhuis A.W. et al. Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. J Clin Psychopharmacol 2006;26:666-667.
Smith J.A. et al. Cocaine increases extraneuronal levels of aspartate and glutamate in the nucleus accumbens. Brain Res 1995;683:264-269.
Snyder S.H. Phencyclidine. Nature 1980;285:355-356.
Sorg B.A., Kalivas P.W. Effects of cocaine and footshocks stress on extracellular dopamine levels in the medial prefrontal cortex. Neuroscience 1993;53:695-703.
Steppuhn K.G., Turski L. Diazepam dependence prevented by glutamate antagonists. Proc Nat Acad Sci USA 1993;90:6889-6893.
Voruganti L.P., Heslegrave R.J., Award A.G. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nervous Mental Dis 1997;185:463-465.
Walker E.F., Diforio D. Schizophrenia: A neural diathesis-stress model. Psychol Rev 1997;104:667-685.
Wise R.A. Drug-activation of brain reward pathways. Drug Alcohol Depend 1998;51:13-22.
Zimmet S.V., Strius R.D., Burgess E.S. et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. J Clin Psychopharmacol 2000;20:94-98.